I have been investing in small and mid-cap biotechs for 4 years. My industry experience as a biostatistician on several phase 1-3 trials helps me with my investment decisions. I usually look for opportunities in oncology, ophthalmology, and neuroscience space.
bio-seeker...of the next biotech breakthrough. Emerging small cap biotech, cancer immunotherapy, PD-1, CD47, RNAi, CAR-T, KIR/NK.
Investing decisions based on information derived from credible sources...clinical trial data, research papers and independent analysis by those who are qualified to analyze... always skeptical of sell side analysis. Never invest based on a single SA article. Always consider the bio of SA authors... 95% can be ignored altogether based on lack of expertise.
Individual investor with particular interest in any company that is on the cusp of change--for the better. These companies will have at least several attributes in common: They are underfollowed; underappreciated; have a clear, stated strategy for driving profits; management and BOD are perfectly aligned with common shareholders; management team and BOD with a track record of rewarding shareholders; and have near-term catalysts that will have meaningful impact on the business. Simple, right?
Portfolio manager, CFA charterholder. Managed $50 million for a market neutral hedge fund and $100 million for Wells Fargo Wealth Management. 17 years of experience, spanning three bull markets and two bear markets.
A career educator with 30 years experience and author of two books, I try to apply my research skills from historical analysis to identifying investments with a good chance for appreciation.
History is my passion and investing is a hobby. I claim no expertise in the financial markets.